JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

LASIK for hyperopia with the WaveLight excimer laser.

PURPOSE: To evaluate the safety and efficacy of the ALLEGRETTO WAVE excimer laser system (WaveLight Laser Technologie AG, Erlangen, Germany) in LASIK for hyperopia and hyperopic astigmatism.

METHODS: One hundred twenty consecutive LASIK cases for hyperopia with or without astigmatism treated with the ALLEGRETTO WAVE excimer laser were prospectively evaluated up to 12 months postoperatively. Patients were allocated into three groups according to their refractive sphere and cylinder: a low hyperopia group, with up to +3.00 diopters (D) sphere and astigmatism < or = +1.00 D (n = 52); a moderate hyperopia group with +3.25 to +5.00 D sphere and astigmatism of < or = +1.00 D (n = 45); and a high hyperopia/toric group with sphere > or = +5.25 D or cylinder > or = +1.25.D (n = 23). Flaps were created with the Moria M2 microkeratome (Moria, Antony, France). Parameters evaluated were pre- and postoperative refractive error, uncorrected visual acuity, best spectacle-corrected visual acuity (BSCVA), higher order aberration change, and contrast sensitivity.

RESULTS: One hundred twelve eyes (93%) were available for follow-up at 12 months. Of the eyes in the low hyperopia group, 92% were within +/- 0.50 D of the refractive goal. For the moderate sphere group and the high hyperopia/toric group, 79% and 71% of eyes, respectively, were within +/- 0.50 D of the refractive goal. No eye lost > or = 2 lines of BSCVA. An increase in higher order aberrations was noted in the high hyperopia/toric group from 0.47 microm (+/- 0.096) to 0.94 microm (+/- 0.167) (P < .001). No significant changes in higher order aberrations were noted in the low and moderate hyperopia groups.

CONCLUSIONS: Hyperopic LASIK using the WaveLight ALLEGRETTO WAVE excimer laser appears to be safe and effective in the correction of low, moderate, and high hyperopia and hyperopic astigmatism.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app